MGC030 — IND submission
Q3 2026
An Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MGC030 is planned for the third quarter of 2026.Source filing
MGNX biotech catalysts & pipeline
MACROGENICS INC · Data as of 2026-09-08
Upcoming catalysts
MGC028 — Initial data
late 2026
The dose escalation study of MGC028 is ongoing and the Company anticipates providing an update with preliminary clinical results in late 2026.Source filing
lorigerlimab — Initial data
H1 2027
The Company is enrolling 20 additional patients with clear cell gynecologic cancer (CCGC) at a dose of 3 mg/kg Q3W and anticipates reporting updated study results in the first half of 2027.Source filing
lorigerlimab — Conference presentation
Oct 23–Oct 27
MacroGenics continues the Phase 2 LINNET study of lorigerlimab, with the interim data accepted for poster presentation at the ESMO 2026 Congress.Source filing
MGC026 — Conference presentation
Oct 23–Oct 27
Interim results from the Phase 1 study have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) 2026 Congress in October.Source filing